Paper
(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
Published Jan 15, 2019 · N. Tzvetkov, H. Stammler, S. Hristova
European journal of medicinal chemistry
Q2 SJR score
15
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
(Pyrrolo-pyridin-5-yl)benzamides show high potency and selectivity as reversible MAO-B inhibitors, with neuroprotective effects on cortical neurons and good BBB penetration in a triple cell neurovascular unit model.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease
Abnormal glycation and glycosylation in proteins may contribute to mitochondria-induced oxidative stress and inflammation in Parkinson's disease, potentially serving as biomarkers for the disease.
2018·63citations·P. Videira et al.·Frontiers in Neuroscience
Frontiers in Neuroscience
Kinetics, mechanism, and inhibition of monoamine oxidase
MAO inhibitors offer antidepressant and behavioral advantages, making them a major pharmaceutical target for inhibitor design.
2018·71citations·R. Ramsay et al.·Journal of Neural Transmission
Journal of Neural Transmission
2018 Alzheimer's disease facts and figures
Early diagnosis of Alzheimer's disease could save up to $7.9 trillion in medical and care costs, with 5.7 million Americans living with dementia and the disease expected to reach 13.8 million by mid-century.
2018·1503citations··Alzheimer's & Dementia
Alzheimer's & Dementia
Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
Recent developments of highly selective and reversible MAOIs have revived the therapeutic potential of these compounds for mental disorders and neurodegenerative diseases like Alzheimer's and Parkinson's disease.
2018·118citations·A. Tripathi et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Signal transduction in l-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression
L-DOPA-induced dyskinesia is caused by sensitization of dopamine receptors in striatal projection neurons, leading to long-term modifications in gene expression and protein synthesis.
2018·41citations·G. Spigolon et al.·Journal of Neural Transmission
Journal of Neural Transmission
Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia
Safinamide inhibits in vivo glutamate release from stimulated nerve terminals, likely through blockade of sodium channels at specific subpopulations of neurons, supporting its anticonvulsant and antiparkinsonian actions.
2018·46citations·M. Morari et al.·The Journal of Pharmacology and Experimental Therapeutics
The Journal of Pharmacology and Experimental Therapeutics
Tautomerism of N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide - A new selective, highly potent and reversible MAO-B inhibitor
NTZ-1006, a highly potent and selective MAO-B inhibitor, exists in solution as a 1H tautomer and its tautomerism is not influenced by solvents or concentration, making it a promising treatment for Parkinson's disease and other neurological disorders.
2017·5citations·N. Tzvetkov et al.·Journal of Molecular Structure
Journal of Molecular Structure
Current approaches to the treatment of Parkinson's Disease.
Current Parkinson's Disease treatments include symptomatic therapies and disease modification approaches, aiming to slow or stop disease progression.
2017·81citations·J. Michael Ellis et al.·Bioorganic & medicinal chemistry letters
Bioorganic & medicinal chemistry letters
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’s Disease
Sembragiline, a novel selective MAO-B inhibitor, shows potent and long-lasting inhibition, with potential therapeutic benefits in Alzheimer's disease and other neurodegenerative disorders.
2017·66citations·E. Borroni et al.·The Journal of Pharmacology and Experimental Therapeutics
The Journal of Pharmacology and Experimental Therapeutics
Citations
Insight into the Interaction of Humulus lupulus L. Specialized Metabolites and Gastrointestinal Bitter Taste Receptors: In Vitro Study in STC-1 Cells and Molecular Docking.
Hop bitter compounds like -acids and xanthohumol increase anorexigenic hormone secretion and taste 2 receptor expression in intestinal cells, offering potential for designing gastrointestinal-permeable T2R agonists.
2024·1citation·Ludovica Lela et al.·Journal of natural products
Journal of natural products
Chemical Space Navigation by Machine Learning Models for Discovering Selective MAO-B Enzyme Inhibitors for Parkinson’s Disease
Machine learning models identified 5 potential lead compounds as potent and selective MAO-B inhibitors, which could be tested for neurodegenerative disease treatment.
2023·4citations·P. Catherene Tomy et al.·Artificial Intelligence Chemistry
Artificial Intelligence Chemistry
In Silico Identification of Multi-Target Ligands as Promising Hit Compounds for Neurodegenerative Diseases Drug Development
In silico approaches identified two promising multi-target ligands for neurodegenerative diseases drug development, reducing research and development costs.
2022·5citations·P. Alov et al.·International Journal of Molecular Sciences
International Journal of Molecular Sciences
Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification.
This review summarizes the pathological mechanisms and potential drugable targets of Parkinson's disease, highlighting the need for novel and safe treatments.
2022·15citations·Zhichao Zhong et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Promising heterocycle-based scaffolds in recent (2019-2021) anti-Alzheimer's drug design and discovery.
Heterocycle-based scaffolds show promise in designing potent anti-Alzheimer's drugs, with some showing pronounced activity and promising structure-activity relationship.
2022·15citations·Atukuri Dorababu·European journal of pharmacology
European journal of pharmacology
Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action.
Compound 5 is a highly potent, selective, and competitive human MAO-B inhibitor with high BBB permeability and neuroprotective action, making it a promising candidate for Parkinson's disease treatment.
2021·12citations·Ahmed Elkamhawy et al.·Bioorganic chemistry
Bioorganic chemistry
Favipiravir tautomerism: a theoretical insight
Favipiravir (T-705) has strong dominance of the enol form in neutral state, but its tautomeric equilibrium shifts towards the keto tautomer in acidic conditions.
2020·27citations·L. Antonov·Theoretical Chemistry Accounts
Theoretical Chemistry Accounts
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Compound 6j, a rasagiline-clorgyline hybrid, shows potential as an effective and promising multitarget agent against Alzheimer's disease due to its high hMAO-B potency and selectivity.
2020·16citations·Sai-Sai Xie et al.·European journal of medicinal chemistry
European journal of medicinal chemistry